Open AccessOptimal duration of adjuvant bisphosphonate treatment for high‐risk early breast cancer: Results from a SUCCESS trial
Author(s) -
Lu Mingbei,
Ren Beibei,
Rao Lingyan
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14257
Subject(s) - medicine , breast cancer , denosumab , oncology , cancer , adverse effect , bisphosphonate , zoledronic acid , osteoporosis